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Abstract
CMV infection is responsible for acceleration of immune senescence and linked to
systemic pathologies, including cardiovascular diseases. In this study, we
investigated differences in the immune response between CMV-seropositive and
seronegative patients undergoing primary percutaneous coronary intervention
(PPCI) for acute myocardial infarction (MI). Peripheral blood samples were taken
at six different time points: pre-, 15, 30, 90min, 24 h after PPCI and at 3 months
after MI. Absolute counts of lymphocyte subpopulations, immune response to
specific and nonspecific stimulation, serum cytokines and levels of CMV-IgG,
cardiolipin-IgG, and anti-endothelial cell antibodies were assessed. CMV-
seropositive patients with MI showed a twofold higher IFN-g production to
PHA-stimulation, up to 2.5-fold higher levels of IP-10 in serum and up to 30%
lower serum levels of IL-16 compared to CMV-seronegative individuals. CMV-
seropositive patients could be divided into two subgroups with high (IL-10Hi) and
low (IL-10Lo) IL-10 serum levels during the acute stage of MI. The IL-10Hi CMV-
seropositive subgroup showed an increased exit of late-differentiated T
lymphocytes, NK and NKT-like cells from the circulation, which may potentially
enhance cytotoxic damage in the ischemic myocardium. Finally, we did not
observe an acceleration of autoimmunity by MI in CMV-seropositive individuals.
The immune response during acute MI showed characteristic differences between
CMV seronegative and seropositive patients, with a stronger pro-inflammatory
response in seropositive patients. The effects of IP-10, IL-16, and IL-10 on
characteristics of acute immune responses and formation of different immune
profiles in CMV-seropositive individuals require further investigation.
Introduction
Every year approximately 25,000 patients in the UK undergo
reperfusion therapy for acute myocardial infarction, in most
cases by primary percutaneous coronary intervention
(PPCI), which involves opening of the blocked coronary
artery followed by placing a stent [1]. Major recent
improvements in PPCI and associated therapies have lead
to a reduction in acute mortality. However, morbidity and
mortality following hospital discharge remains significant [1,
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2]. There are two major reasons for this, the first of which
relates to the size of the infarct, culminating in left
ventricular dysfunction and eventually leading to heart
failure. The other is the accelerated progression of
atherosclerosis following myocardial infarction (MI), which
could be explained by the pro-inflammatory state of such
patients. While the immune system, and in particular
lymphocytes, regulate inflammation, their role in myocar-
dial infarction has not been investigated in detail.
Human cytomegalovirus (CMV) is a ubiquitous herpes
virus that even after recovery from acute infection is never
cleared from the human body. Chronic CMV infection leads
to phenotypic changes in the immune system, most visible in
the T-cell compartment, coinciding with clonal expansion
and preferential accumulation of CD8þCD45RAþCD27
cytotoxic T cells [3, 4]. Clinically, CMV has been linked to an
increased incidence of coronary heart disease and an
increased risk of cardiovascular death in people over the
age of 65 years without an increase in other causes of
mortality [5]. We have shown previously a link between
immunosenescence and coronary artery disease [6, 7].
We have also recently published on the impact of the
myocardial ischemia and reperfusion on absolute counts of
T cells in peripheral blood: predominantly CD4þ and CD8þ
late-differentiated T-cell subpopulations fell dramatically
within the first hour after reperfusion, followed by a increase
to prior PPCI levels at the 24-h time point [6, 8].
We hypothesized that a higher proportion of the late-
differentiated T-cell populations leave the blood circulation
after reperfusion inMI in CMV-seropositive patients than in
CMV-seronegative patients, which may have a negative
effect on reperfusion injury in MI leading to a larger infarct
size.
The aim of this study was to investigate differences in the
immune response between CMV seropositive and seronega-
tive patients undergoing reperfusion therapy for acute
myocardial infarction.
Material and Methods
Patient population
A cohort of 52 patients with ST elevation myocardial
infarction (STEMI) were prospectively identified and
enrolled in the study at the time of admission. Inclusion
criteria were chest pain of onset within 6 h with new ST
segment elevation on electrocardiogram. Exclusion criteria
were cardiogenic shock, previous MI, active infection or
malignancy, chronic inflammatory conditions, patent
arterial flow in the infarct related artery, and any exclusion
to cardiac MRI. Written informed consent was obtained
from all patients. Patient characteristics are displayed in
supplemental Table S1. The study protocol was approved by
the NHS HRA committee (REC 12/NE/0322).
Blood sampling
Arterial blood was taken before reperfusion and at 15,
30, and 90min following reperfusion. Venous blood
samples were obtained at 24 h and after 3–6 months
post-PPCI.
Clinical tests
CMV and EBV serostatus as well as baseline values of general
blood analysis, lipid panel, glucose, creatinine, and 12-h
troponin levels were assessed at the Freeman Hospital
Laboratory.
Flow cytometry
All FACS analysis was performed using BD FACS Canto II
flow cytometer with FACSDiva software (BD Biosciences,
San Jose, CA, USA). A minimum of 10,000 events for a
population of interest were recorded for each sample.
Identification of lymphocyte subpopulations
Patients’ blood was collected in EDTA tubes (BD
Biosciences) at 6 time points: pre-, 15, 30, 90min and
24 h post reperfusion as well as 3 months after the acute
event. Whole blood samples were used for quantification of
absolute counts and percentage distribution of lymphocyte
subpopulations by multicolor flow cytometry. Absolute
counts of granulocytes, monocytes, CD4þ and CD8þ
T lymphocytes were measured using the BD MultiTEST
cocktail (anti-CD3-FITC, CD8-PE, CD45-PerCP,
CD4-APC) and BD Trucount tubes (BD Biosciences).
NK and NKT-like cells as well as naı¨ve (CCR7þCD45RAþ),
central memory (CCR7þCD45RA), effector memory
(CCR7CD45RA) and terminally differentiated effector
memory (CCR7CD45RAþ) subpopulations of CD4þ and
CD8þ T lymphocytes were identified with the following
monoclonal antibodies: anti-CD3-FITC, CD4-V500, CD8-
APC-H7, CD16-PE, CD27-APC, CCR7(CD197)-PE-Cy7
(BD Biosciences), CD45RA-Pacific Blue (Invitrogen) and
CD56-PerCP-eFluor710 (eBioscience, San Diego, CA,
USA). Following incubation with these antibodies, samples
were lysed, washed and immediately analyzed on a flow
cytometer.
Quantification of regulatory T cells
Regulatory T cells (Tregs) were measured in EDTA whole
blood samples collected at 3 time points only: pre-
reperfusion and 90min and 24 h post reperfusion. Firstly,
for surface staining, blood samples were incubated with anti-
CD3-PerCP, CD4-V500, CD25-APC (BD Biosciences)
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monoclonal antibodies, lysed by BD Pharm Lyse (BD
Biosciences) and washed twice with PBS containing 5% fetal
calf serum (5% FBS/PBS). After fixation and permeabi-
lization (BD Pharmigen Human FoxP3 Buffer Set, BD
Biosciences), cells were incubated with an anti-FoxP3-PE
monoclonal antibody (BD Biosciences) for intracellular
staining. Finally, samples were washed and analyzed on a
flow cytometer. PE Mouse IgG1, k Isotype (BD Biosciences)
was used to exclude nonspecific binding.
Measurement of CMV-specific CD8þT cells
HLA typing of CMV-seropositive patients was performed by
NHS Blood and Transplant Newcastle. CMV-specific CD8þ
T cells were identified in PBMCs isolated from pre-PPCI,
90min, 24 h and 3-month blood samples as published
previously [6]. In brief, cryopreserved PBMCs were quickly
thawed and washed with 5% FBS/PBS before cell viability
was determined using a Vi-CELL Cell Viability Analyzer
(Beckman Coulter). 1 106 cells then were incubated with
HLA-matched MHC Dextramer-PE (Dextramer CMV Kit,
Immudex) for 10min, followed by 20min incubation with
anti-CD3-FITC, CD27-APC, CD8-APC-H7, CD45RA-Pa-
cificBlue (BD Biosciences). Finally, cells were washed twice
with 5% FBS/PBS and assessed by FACS. PE-Negative
control (Dextramer CMV Kit, Immudex) was used to
exclude nonspecific binding.
ELISPOT assay
Cryopreserved PBMC were quickly thawed, washed and
resuspended in RPMI 1640 medium (Sigma, Dorset, UK)
supplemented with penicillin (100U/mL), streptomycin
(100mg/mL), L-glutamine (2mM) (Invitrogen, Paisley, UK)
and 10% heat-inactivated FBS (Biosera, Uckfield, UK).
PBMC were set up for ex-vivo ELISPOT at 8 106/mL
(50mL/well of capture antibody-coated Millipore plate) for
20 h incubation, as optimized and described previously [6,
9]. ELISPOT kits were purchased from Mabtech (Nacka,
Sweden) and manufacturer’s instructions followed for plate
development, withmodifications as previously described [9].
. The CMV and EBV viral antigenic stimuli used, were pools
of known CD8 epitope peptides (10mg/mL) for CD8
responses [10] and pools of known CD4 epitope peptides
(10mg/mL) plus viral lysates for CD4 responses. Medium-
only and phaetohaemagglutinin (PHA, 5mg/mL) controls
were used in all assays. Measurement of polyclonal secretion
of IL-5, IL-17 and IL-2 was carried out using PHA as the
stimulus, and ELISPOT reagents from Mabtech (IL-5),
eBioscience (IL-17), or R&D Sytems (IL-2), again following
manufacturer’s instructions. Results are expressed as spot-
forming cells/106 PBMC (net antigen-stimulated spots
minus medium).
Cytokine measurement
Thirty one cytokines were assessed in serum samples (pre-,
15, 30, 90min, 24 h and 3-month time points) using human
the IL-18 kit and human cytokine 30-Plex Kit, V-PLEX,
Meso Scale Discovery (containing IFN-g, IL-1b, IL-2, IL-4,
IL-6, IL-8, IL-10, IL-12p70, IL-13, TNFa, GM-CSF, IL-1a,
IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-b,
VEGF, Eotaxin, MIP-1b, Eotaxin-3, TARC, IP-10, MIP-1a,
MCP-1, MDC, MCP-4) on a SECTOR Imager instrument
(Meso Scale Discovery, Rockville, MD, USA) according to
manufacturers’ protocols.
ELISA assays
ELISA kits were used to quantify CMV IgG-specific
antibodies in CMV-seropositive patients (Cat. Number:
40-052-115031, GenWay Biotech) and detect human anti-
endothelial cell antibody, AECA (Cat. Number: CSB-
E08691h, CUSABIO) as well as anti-cardiolipin IgG
antibody (Cat. Number: 40-101-325062, GenWay Biotech)
according to the manufacturers’ protocols.
Statistical analysis
SPSS version 21 and GraphPad Prism version 6 were used for
statistical analysis. For comparisons between two groups
non-parametric Mann–Whitney U-test and paired Wil-
coxon test were used, and for analysis of more than two
groups two-way repeatmeasurements (RM)ANOVA tests. P
values <0.05 were considered significant. Correlations were
analyzed by Spearman’s correlation analysis. Corresponding
tests are indicated in the text. Data are presented as median
with low and upper quartiles.
Results
Baseline characteristics of patient population
All 52 patients with acute myocardial infarction (STEMI)
underwent reopening of their occluded coronary artery by
PPCI, leading to immediate reperfusion. As expected, CMV-
seropositive patients were slightly older than CMV-negative
patients (62 vs. 56 years, P¼ 0.033, supplemental Table S1).
Clinical tests included a full blood analysis, lipids, creatinine,
glucose, and troponin levels (Supplemental Table S1). Infarct
size, estimated by peak troponin levels, did not differ between
the two study groups (4800 vs. 5098, P¼ 0.93).
Lymphocyte subpopulations in CMV-seropositive
and seronegative patients
Our results demonstrated increased absolute counts of late-
differentiated effector memory (EM) and CD45RAþ effector
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memory (TEMRA) CD4þ and CD8þ T lymphocytes (CD4/
8þCD45RA/þCCR7CD27 T-subsets), as well as NKT-
like cells (CD3þCD56þ) in CMV-seropositive individuals, in
keeping with previously published findings (Fig. 1A) [11,
12]. This pattern persisted across all time points of acute MI
(Supplemental Table S2). CMV-seropositive and seronega-
tive patients showed a significant cell loss of CD4þ and
CD8þ CD45RAþ/CCR7CD27 T-subpopulations as well
as NK and NKT-like cells during 90min after reperfusion,
followed by a gradual increase to prior-PPCI levels at the 24-
h time point. This trend was the same for both CMV-
seropositive and seronegative patients (Supplemental
Table S2). Furthermore, the subpopulations had similar
percentages of cell drops in both groups of patients (on
average 40–60%; Fig. 1B). At 3 months, the described cell
types were fully recovered.
Among CMV-seropositive patients, there was a wide
variation regarding the total numbers of CD4þ and CD8þ
effectormemory/TEMRAT cells. Correlation analysis revealed
an association between the number of late differentiated T cells
and their drop following reperfusion (Fig. 2A), as well as
that of NKT-like cells (Fig. 2B). Moreover, absolute counts
of NKT-like cells positively correlated with the level of
CCR7CD27 T cells (Fig. 2C). The pre-PPCI number of NK
cells also correlated with their drop (Fig. 2D).
CMV-seropositive men showed higher levels of
CD8þCCR7CD27 T cells than CMV-seropositive women
(Fig. 2E). Furthermore, there was a positive correlation
between the peak troponin level, reflecting infarct size, and
the magnitude of drop in CD4þCCR7 T lymphocytes for
CMV-seropositive men (Spearman correlation; r¼0.491,
P¼ 0.039) (data not presented).
Regulatory T cells (Treg; CD3þCD4þCD25highFoxP3þ)
were measured before as well as 90min and 24 h after
reperfusion. There was a significant difference in the
absolute count of Treg cells only before reperfusion, with
CMV-seropositive patients showing lower Treg cell levels
than CMV-negative individuals (Fig. 2F, Supplemental
Table S2).
CD8þ CMV-specific T-cell dynamics
We next analyzed the dynamics of CMV-specific CD8þT
cells (CD3þCD8þCMV dextramerþ) following reperfusion.
The percentage of CMV dextramerþCD8þT cells declined at
90min and returned to pre-PPCI levels at the 24-h time
point (Fig. 3A). Interestingly, the percentage of CMV-
specific cells among CD8þ T lymphocytes at 3 months was
significantly lower than in acute MI before PPCI. The
percentage drops of CD8þ effector memory/TEMRA T cells
and CMV-specific CD8þ T cells were similar (Fig. 3B).
Subpopulation analysis revealed that CD27 cells made
up 80% of CD8þCMV dextramerþ T cells inMI (Fig. 3C and
D). The composition of CMV-specific cells did not show
significant changes during the acute stage of MI.
ELISPOT results
To characterize the antigen-specific response functionally,
we measured IFN-g production by CD4þ and CD8þ
T lymphocytes using ELISPOT. While the CMV-specific
CD8þ T-cell response remained unchanged across all time
points (Fig. 4A), we saw a transient drop in the CD4þ T-cell
immune response to CMV-peptide stimulation at 90min
after PPCI (Fig. 4B).
To investigate the immune response against other herpes
viruses we stimulated PBMCs of EBV-seropositive patients
with CD8 or CD4 epitope EBV peptides. CMV-seropositive
and seronegative individuals did not differ in levels of CD4þ
and CD8þ T-cell EBV-specific responses (data not shown).
The reaction to EBV-peptides declined at 90min after PPCI
in CMV-seropositive and seronegative patients, regardless of
CMV serostatus (Fig. 4C and D). As expected, the CMV-
specific response was much stronger than the response to
EBV-stimulation, especially for CD8þ T lymphocytes.
Importantly, IFN-g secretion by CD8þ T cells was
approximately 10-fold higher than by CD4þT lymphocytes.
To investigate differences in nonspecific T-cell responses,
we measured PHA-induced production of IL-2, IL-5, IL-17,
and IFN-g (Fig. 4E–G). There were no differences in IL-2,
IL-5, and IL-17 secretion between CMV-seropositive and
seronegative individuals. However, CMV-seropositive pa-
tients had a two to threefold higher PHA-induced IFN-g
secretion (P¼ 0.0002; two-way RM ANOVA) across all time
points than CMV-seronegative individuals. Furthermore,
there was a significant drop of IFN-g secretion in both
patient groups at 90min after reperfusion, which returned to
baseline levels after 24 h (Fig. 4H).
Serum cytokine levels in CMV-seropositive and
seronegative patients
Among 31 detected serum cytokines, CMV-seropositive and
seronegative patients differed only in pre- and post-
reperfusion levels of IL-16 (P¼ 0.0003; two-way ANOVA)
and IP-10 (P< 0.0001; two-way ANOVA) in acute MI.
CMV-seropositive patients had higher levels of IP-10 and
lower level of IL-16 (Table 1, Fig. 5A and B). Also, the
dynamics of IP-10 changes were opposite to the cell drops at
the measured time points. More pronounced changes were
registered within the first 15min after reperfusion, when IP-
10 increased up to twofold. However, there were no
significant correlations between cell counts and IP-10 levels
(data not presented).
The serum concentration of IL-16 fluctuated slightly at
the acute stage of MI (Table 1). Furthermore, there was an
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inverse correlation between the magnitude of the
CD4þCCR7þ/ T-lymphocyte drop and the dynamics of
IL-16 secretion: the more IL-16 increased in the period up to
90min after PPCI (D pre-90min after PPCI), the more
CD4þ T lymphocytes declined at the same time interval
(Spearman correlation; r¼0.523, P¼ 0.009) (Supplemen-
tal Fig. S1). Also, the high level of IL-16 at the 90min time
point was associated with a more pronounced decrease of
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IFN-g response to PHA-stimulation (D pre-90min after
PPCI) (Spearman correlation; r¼0.521, P¼ 0.027).
Serum samples taken at 3 months contained higher
concentrations of IP-10 (533 vs. 297 pg/mL; P¼ 0.017,
Mann–Whitney), IL-17A (3.29 vs. 1.04 pg/mL; P¼ 0.008,
Mann–Whitney) and IL-10 (0.51 vs. 0.19 pg/mL; P¼ 0.008,
Mann–Whitney) in CMV-seropositive compared to sero-
negative patients.
IL-10Hi and IL-10Lo subgroups of
CMV-seropositive patients
Serum levels of IL-10 were measured in 40 patients. As
indicated above, CMV-seropositive and seronegative
patients had different levels of IL-10 only at the 3-month
time point. Nonetheless, since the CMV-seropositive group
showed heterogeneous results for serum levels of IL-10,
we compared patients with high (IL-10Hi; n¼ 9) and low
(IL-10Lo; n¼ 12) levels of IL-10 (Fig. 5C–L). These two
CMV-seropositive subgroups had significantly different
serum concentrations of IL-10 (P¼ 0.002; two-way RM
ANOVA) in the acute stage of MI (Fig. 5C). Also, IL-10Hi
and IL-10Lo subgroups could be distinguished from CMV-
seronegative patients (P¼ 0.01 and P¼ 0.004, respectively;
two-way RM ANOVA). As shown in Figure 5D, IL-10
concentration in the IL-10Lo CMV-seropositive subgroup
remained at a constant low, while the other patients had
high IL-10 levels before as well as 15, 30, and 90min after
Table 1. Serum levels of IP-10 and IL-16 in CMV-seropositive and seronegative patients at different time points.
CMV status Time points
Median (25% quartile;
75% quartile), pg/mL p1 p2 p3 p4 p5
IL-16
Positive Acute MI, n¼ 11
Before PPCI 162 (108; 199)
After PPCI
15min 137 (92; 216) 0.322
30min 125 (106; 210) 0.770 0.922
90min 191 (149; 228) 0.123 0.375 0.160
24 h 162 (117; 186) 0.520 0.846 0.322 0.083
3 months after acute MI, n¼ 5 261 (173; 304) 0.145 0.129 0.055 0.267 0.052
Negative Acute MI, n¼ 14
Before PPCI 237 (170; 309)
After PPCI
15min 213 (141; 286) 0.424
30min 170 (123; 257) 0.007 0.339
90min 271 (206; 303) 0.636 0.240 0.011
24 h 203 (160; 253) 0.204 >0.999 0.339 0.151
3 months after acute MI, n¼ 6 187 (148; 333) 0.518 0.918 0.493 0.606 0.849
IP-10
Positive Acute MI, n¼ 11
Before PPCI 272 (183; 294)
After PPCI
15min 608 (338; 964) 0.002
30min 549 (416; 726) 0.004 0.695
90min 418 (284; 602) 0.005 0.01 0.02
24 h 250 (215; 539) 0.054 0.002 0.006 0.102
3 months after acute MI, n¼ 5 533 (418; 701) 0.002 0.554 >0.999 0.180 0.052
Negative Acute MI, n¼ 14
Before PPCI 169 (116; 205)
After PPCI
15min 301 (256; 373) 0.002
30min 315 (200; 394) <0.001 0.519
90min 244 (172; 296) 0.013 0.003 0.005
24 h 213 (164; 271) 0.034 0.084 0.034 0.622
3 months after acute MI, n¼ 6 297 (234; 362) 0.005 0.647 0.863 0.152 0.053
P values for different time points by paired Wilcoxon test. p1: P values for corresponding time point and parameter before PPCI; p2: P values for
corresponding time point and parameter at 15min after reperfusion; p3: P values for corresponding time point and parameter at 30min after reperfusion;
p4: P values for corresponding time point and parameter at 90min after reperfusion; p5: P values for corresponding time point and parameter at 24 h after
reperfusion. Significant values in bold.
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Figure 5. Serum levels of IP-10, IL-16 and IL-10 in CMV-seropositive and seronegative individuals. Serum levels of IP-10 (A) and IL-16 (B) in CMV-
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reperfusion. However, IL-10Hi CMV-seropositive patients
had almost a threefold higher magnitude of IL-10 than
CMV-seronegative study participants. The described differ-
ences were observed only during the acute stage of MI,
yet lL-10 levels were equal at 3 months in both subgroups
of CMV-seropositive subjects and were higher than in
CMV-seronegative individuals (stated above) (Supplemental
Fig. S2).
Interestingly, glucose levels were higher in the IL-10Hi
than in the IL-10Lo subgroup (9.2 vs. 6.2; P¼ 0.018, Mann–
Whitney). Furthermore, the cell decrease described above
was more pronounced for IL-10Hi CMV-seropositive
patients. Figure 5E–H illustrates significant differences in
the magnitude of cell drops for CD8þCD45RAþ/
CCR7CD27 T lymphocytes, NK and NKT-like cells
between the subgroups. Also, the change in serum IL-10
concentration after PPCI correlates with the drops of these
lymphocyte subpopulations (Fig. 5I–L).
In addition, IL-10Hi patients had a very sharp increase
of IP-10 levels in serum after 15min of reperfusion, in
contrast to the IL-10Lo subgroup (828 (IL-10Hi) versus 484
(IL-10Lo); P¼ 0.044, Mann–Whitney).
Autoimmunity and MI
To evaluate a potential impact of MI on autoimmune drive,
the presence of anti-endothelial cell antibodies (AECA)
and cardiolipin autoantibodies were measured in 24 h and
3-month samples using ELISA assays. AECA were found in
3 CMV-seropositive and 3 CMV-seronegative patients.
One of these CMV-seronegative individuals had AECA at
the 3-month time point only, but not during the acute
stage of MI. Anti-cardiolipin antibodies were detected in
6 CMV-seropositive patients and 7 CMV-seronegative
patients at both time points.
In addition, we measured CMV IgG antibodies in serum
samples taken at the 24 h and 3-month time points. No
increase of CMV specific IgG titer was registered at 3 months
after MI.
Discussion
We have shown previously that reopening of an occluded
coronary artery with PPCI during acute MI leads to an acute
depletion of T cells from peripheral blood [6]. This was
associated with lymphocyte exit from the circulating
bloodstream. In this study, we demonstrate that CMV-
seropositive and seronegative patients show different
dynamics in nonspecific IFN-g production, as well as IP-
10 and IL-16 expression in the serum during acute MI. In
addition, CMV-seropositive patients with high IL-10 levels
demonstrated an increased drop of cytotoxic lymphocyte
populations during reperfusion, which may suggest a worse
clinical outcome, given the previously published association
between low lymphocyte counts and increased mortality in
MI [13].
Depletion of cytotoxic lymphocyte populations
during acute MI
Since CMV-seropositive individuals had higher baseline
numbers of late-differentiated T lymphocytes and NKT-like
cells, the absolute count of ‘‘missing’’ cells after reperfusion
was much larger in CMV-seropositive than in CMV-
seronegative patients. Furthermore, pre-PPCI absolute
counts of CD45RAþ/CCR7CD27 T lymphocytes, NK
and NKT-like cells negatively correlated with percentages of
their drop. We speculate that these cells may be lost from the
circulation in part through sequestration into inflamed
tissues, including reperfused myocardium. Given that these
lymphocyte populations are known to have cytotoxic
activity [14, 15], we hypothesized correlations between
prominent cell loss and severity of the clinical picture and
infarct size. However, there was only one significant
correlation, which demonstrated the relationship between
CD4þCCR7 T-cell decline intensity and troponin level
reflecting infarct size, but only for CMV-seropositive males.
The depletion of CMV-specific CD8þ T lymphocytes in
blood from CMV-seropositive patients resembled the drop
in late-differentiated T cells. This can be explained by the fact
that approximately 80% of CMV dextramerþCD8þ T cells
showed a CD45þ/CD27 phenotype (late-differentiated
CMV-specific CD8þ T lymphocytes). However, the balance
of CD45þ/CD27þ and CD45þ/CD27 CMV dextramerþ
T-subpopulations remained constant within the acute stage
of MI suggesting that the migratory ability of these subsets
was equal.
Antigen-specific and PHA-related response in
CMV-seropositive and seronegative individuals
The ELISPOT analysis revealed a decrease in EBV-induced
IFN-g secretion by CD4þ and CD8þ T cells and CMV-
induced IFN-g secretion by CD4þ T lymphocytes at 90min
post reperfusion, while CD8þ T-cell IFN-g production to
CMV-antigen remained stable during all time points.
Consequently, we concluded that the decrease in IFN-g
secretion was a result of cell anergy rather than a drop in
number of IFN-g-producing cells in the PBMC samples. A
similar decline of cytokine secretion was observed when
PBMCs were incubated with a non-specific stimulator
(PHA). A decrease in cytokine production was observed only
for IFN-g and IL-2, but not for IL-5 and IL-17. T-cell anergy
is an important mechanism of immune tolerance, which
preserves immune homeostasis and prevents autoimmunity.
T-cell anergy leads to decreased secretion of IL-2 and IFN-g,
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reduced response to antigens and inhibition of proliferation
as well as effector function [16, 17]. Recently we have
published that upregulation of PD1 (an inhibitory receptor)
expression on T lymphocytes leads to functional anergy and
high susceptibility to apoptosis of CMV-specific cells in
STEMI patients undergoing PPCI [6]. In the current study,
anergy was shown in EBV-specific responses of CD8þ and
CD4þ T cells and CMV-specific response of CD4þ T cells at
the 90min time point. However, CD8þ CMV-specific T
lymphocytes retained their full effector function for longer,
suggesting a lack of self-termination mechanisms, which
may lead to escalation of inflammation.
As for increased PHA-mediated IFN-g secretion in CMV-
seropositive subjects, this fact could be a result of an
enhanced proportion of late-differentiated T lymphocytes
and NKT-like cells secreting a high amount of IFN-g [18].
Low IL-16 level in serum of CMV-seropositive
patients with acute MI
We describe for the first time a decrease of IL-16 levels in
CMV-seropositive patients in the acute stage of MI. IL-16 is
produced by CD8þ and CD4þ T lymphocytes, dendritic
cells, eosinophils, mast cells, monocytes, fibroblasts, epithe-
lial, and neural cells [19]. IL-16 is widely known as a
chemoattractant capable of inducing the migration of CD4þ
T lymphocytes and other cells which express CD4:
eosinophils, monocytes, dendritic cells [19, 20]. Our results
also showed a correlation between the CD4þ T-cell drop and
serum levels of IL-16, which may play a role in the capability
of immune defense during pathogen invasion or termination
of excessive inflammation via Treg attraction. Interestingly,
McFadden and co-authors provided proof of preferential
recruitment and expansion of Treg lymphocytes in
inflammatory areas mediated by IL-16 [21]. In our study,
CMV-seropositive patients had a lower absolute count of
Treg cells than CMV-seronegative individuals in the acute
phase of MI.
IL-16 not only has a chemoattractant function, but also
has the ability to influence TCR-mediated activation, as it is
a ligand for the CD4 molecule [22]. It has been shown that
IL-16 inhibits the mixed lymphocyte reaction [22] and has
an immunosuppressive effect on Th2 response [23]. In
addition, administration of rIL-16 decreases IFN-g, IL-1b,
and TNF levels in engrafted human inflamed rheumatoid
synovium [24]. We also showed decreasing IFN-g produc-
tion in the ELISPOT assay when the IL-16 serum level was
high, which might be explained by the fact that IL-16 links to
the CD4 receptor. Nonetheless, a wide range of immunos-
timulatory/pro-inflammatory IL-16 effects have been
described as well [19, 25]. Cruikshank and co-authors
suggested a hypothesis where IL-16-mediated recruited cells
would retain the ability to respond to cytokine, but not to
antigen-specific activation [19]. Acute MI causes aseptic
inflammation [26]; therefore downregulation of antigen-
specific cells is required. Due to the fact that late-
differentiated memory CD4þ T cells very often showed
crossreactivity [27], alloreactivity [28] and autoreactiv-
ity [29–31], the lack of IL-16 and Treg lymphocytes may lead
to enhanced inflammation and eventually promotion of
autoimmunity.
High IP-10 serum level in CMV-seropositive
individuals
IP-10 (C-X-C motif ligand 10, CXCL10) is an IFN-g-
inducible chemokine secreted by numerous cell types
including monocytes, neutrophils, endothelial cells, fibro-
blasts, keratinocytes, T lymphocytes, NK, and NKT-like
cells [32]. It acts though its receptor CXCR3 and leads to
recruitment of T lymphocytes, NK cells, eosinophils, and
monocytes [33]. In our study, the more pronounced drop of
late-differentiated T lymphocytes and NK cells might be a
consequence of the fact that the chemokine receptor CXCR3
is predominantly expressed on activated memory T
lymphocytes and NK cells [34]. The increased IP-10 level
in serum of CMV-seropositive patients in our study was not
surprising, owing to the fact that the IFN-g/IP-10 loop is
known to contribute in other viral infections as well as
autoimmune diseases [32, 35–37]. However, our results did
not show correlations between IFN-g and IP-10 levels,
nor an increased level of IFN-g per se in serum of
CMV-seropositive individuals.
Heterogeneity of CMV-seropositive patients and
IL-10 serum levels
Secreted by dendritic cells, macrophages, T- and B-
lymphocytes [38], IL-10 is widely considered an immuno-
suppressant. However, a large number of original articles
and reviews are dedicated to the dual function of IL-10 [39,
40]. Numerous papers demonstrate antitumor activity of
IL-10 due to its effect on NK cells and cytotoxic T
lymphocytes [41, 42]. IL-10 downregulates mainly CD4þ
T cells, yet it promotes the cytotoxic ability of CD8þ T
lymphocytes and especially NK cells and enhances IFN-g
production by these cells [42–44]. Furthermore, it has been
published that the immunosuppressive function of IL-10 is
related mainly to naı¨ve T cells via inhibition of the
costimulatory receptor CD28 [45]. Mocellin and coauthors
concluded that IL-10 is capable of suppressing naı¨ve cell
priming by dendritic cells, which leads to immune tolerance
and downregulation of autoaggression, whereas it stimulates
activity of antigen-experienced cells [46].
Importantly, patients from the IL-10Lo subgroup had
much smaller drops of NK cells, CD8þ effector memory and
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TEMRA T lymphocytes, as well as NKT-like cells, than the
IL-10Hi patients. Our results also showed that the IP-10 level
in the IL-10Hi patients increased much faster after
reperfusion than in the IL-10Lo subgroup. Several papers
also support the concept of upregulation of cell migration-
related genes by IL-10 [41, 43, 47]. In other words, the
possibility of cytotoxic damage of ischemicmyocardiumwas
lower in IL-10Lo patients, which is certainly beneficial for
patients with STEMI. Supporting this conclusion, Derho-
vanessian and coworkers showed that IL-10 production in
response to antigen stimulation correlated with worse
survival in CMV-seropositive elderly individuals [11]. It is
important to note that the two subgroups of CMV-
seropositive patients had different levels of IL-10 only at
the acute stage of MI, but not at the 3-month time point.
In this study, we performed a comprehensive analysis of
differences in characteristics of immune reactions in CMV-
seropositive and seronegative individuals at the acute stage
of MI, which can serve as a good in vivo model for
investigation of acute reactive inflammation in the human
organism.We have shown that IL-10, IL-16, and IP-10 play a
significant role in the determination of various immune
profiles of CMV-seropositive and seronegative patients at
the time of acute MI. With CMV-seropositivity, high levels
of IL-10 and IP-10 in serum, as well as low concentrations of
IL-16 may be deleterious for patients with STEMI. Thus, the
influence of CMV infection on IL-16 and IL-10 dynamics in
acute inflammation merits further investigation.
Limitations
The described percentages of CD8þ CMV-specific T cells
and their subpopulations were based on a restricted number
of HLA types: A0101, A0201, A0301, A2402, B0702,
B0801, B3501.
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